Skip to content

    Sun Pharmaceutical Industries Limited

    India's largest drugmaker and 13th-largest US generics maker, selling specialty and generic drugs in 100+ countries

    Healthcare
    Healthcare
    View SUNPHARMA earnings calls
    ₹1,838.3
    +3.05% from avg

    Overview

    Price

    ₹1,838.3

    Market Cap

    ₹4.7L Cr

    Sector

    Healthcare

    Healthcare

    Rank

    4

    Performance

    Explore SUNPHARMA

    Promise TrackerConcall Analysis

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY19FY20FY21FY22FY23FY24FY25FY26TTM
    LiabilitiesEquity Capital240240240240240240240240240
    Reserves41.2k45.0k46.2k47.8k55.8k63.4k72.0k77.6k83.3k
    Borrowings10.5k8.3k3.9k1.3k6.9k3.3k2.4k5.2k4.6k
    Other Liabilities12.7k14.6k17.3k20.5k17.8k18.4k17.3k20.7k20.2k
    Total Liabilities64.6k68.2k67.6k69.8k80.7k85.3k91.9k103.7k108.4k
    AssetsFixed Assets21.8k22.8k21.6k22.7k24.1k23.2k22.6k33.4k32.8k
    CWIP1.4k1.2k1.6k1.3k5.0k5.4k6.6k1.4k3.1k
    Investments7.9k10.1k9.6k12.8k14.8k15.0k18.4k19.5k24.7k
    Other Assets33.4k34.0k34.9k33.0k36.8k41.7k44.3k49.4k47.8k
    Total Assets64.6k68.2k67.6k69.8k80.7k85.3k91.9k103.7k108.4k

    Valuation

    Assumptions

    Current — SUNPHARMA
    Price
    ₹1,838
    EPS (TTM)
    ₹47.85
    PE (TTM)
    38.4
    Profit growth
    10.6%
    ₹

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (36.7×) and current (38.4×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹1,838
    vs
    Fair value · 15% return
    ₹1,264
    31%Overvalued

    At 10.6% growth and a 37× exit, ₹1838 only delivers your return if you pay ₹1,264. The price is currently baking in 18% growth.

    EPS grows 10.6%/yr for 5 years, then fades to 6% over 2, exits at 37×.

    YearGrowthEPS (₹)
    FY2710.6%52.92
    FY2810.6%58.53
    FY2910.6%64.74
    FY3010.6%71.60
    FY3110.6%79.19
    FY328.3% ·fade85.76
    FY336.0% ·fade90.91

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Sun Pharmaceutical Industries Limited

    Guides on how to read this kind of business and the numbers that matter.